Intellia Therapeutics, Inc. insider trading

Bought

—

Sold

$531.6K

3 of 7 on a 10b5-1 plan

Net

−$531.6K

Insiders

5

• Leonard John M10b5-1

  President and CEO · Director

  −$36.2K

  Aug 21, 2026

  2,785 sh · $13.00

• Leonard John M10b5-1

  President and CEO · Director

  −$250.6K

  Aug 20, 2026

  19,890 sh · $12.60

• Dulac Edward J III

  EVP, Chief Financial Officer

  −$91.2K

  Jul 22, 2026

  8,111 sh · $11.25

• Dulac Edward J III10b5-1

  EVP, Chief Financial Officer

  −$84.2K

  Jul 02, 2026

  4,677 sh · $18.00

• Dube Michael P

  VP, Chief Accounting Officer

  −$44.3K

  Jul 01, 2026

  2,641 sh · $16.78

• Basta James

  EVP, General Counsel

  −$16.7K

  Mar 02, 2026

  1,211 sh · $13.78

• Clark Eliana

  EVP, Chief Technical Officer

  −$8.4K

  Mar 02, 2026

  607 sh · $13.78

Largest purchase

+$1.4M of NTLA by Cohen Fred E (Director) on Jan 05, 2026.

Largest sale

−$474.1K of NTLA by Leonard John M (President and CEO · Director) on Dec 11, 2025, under a 10b5-1 plan.

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

SEC industry classification

In Vitro & In Vivo Diagnostic Substances

Headquarters

Cambridge, MA

Incorporated in

DE

Listed on

Nasdaq

SEC Central Index Key

0001652130

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

Open-market purchase (code P)

An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.

Grants and option exercises (codes A, M)

Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.

Cluster buy

Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Are NTLA insiders buying or selling?

Between Mar 02, 2026 and Aug 21, 2026, 5 Intellia Therapeutics, Inc. insiders made no open-market purchases and 7 sales worth $531.6K, a net sale of $531.6K. 3 of the sales were pre-scheduled under a Rule 10b5-1 plan.

How much NTLA stock have insiders bought and sold in the last two years?

Between Jul 01, 2024 and Jun 30, 2026, 13 Intellia Therapeutics, Inc. insiders made 2 open-market purchases worth $2.4M and 33 sales worth $2.7M. 7 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 2 purchases ($2.4M) and 18 sales ($1.8M). The largest purchase was Cohen Fred E buying $1.4M on Jan 05, 2026. The largest sale was Leonard John M selling $474.1K on Dec 11, 2025.

What was the largest recent NTLA insider trade?

Leonard John M (President and CEO · Director) sold $250.6K of NTLA stock on Aug 20, 2026 at about $12.60 a share, under a pre-scheduled 10b5-1 plan.

When did an insider last buy NTLA shares?

No open-market purchase by a Intellia Therapeutics, Inc. insider appears in the filings from Mar 02, 2026 to Aug 21, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Cohen Fred E buying $1.4M on Jan 05, 2026.

Where does NTLA insider trading data come from?

From the Form 4 filings Intellia Therapeutics, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.